“And I expect that momentum that we are building this year to carry through to next year.”

In context

“stics, the introducers, the ice catheter. I mean, all of that matters. And that is what our focus is here is to really position ourselves as a as a as a leading company, in this space And we have got a nice pipeline of PFA catheters still in the works So between now and 2029, we will have iterations and new versions and new ideas come out. But, we are also equally investing in mapping and ensuring that our mapping superiority, is maintained. As obviously competitors are launching their own mapping systems. So we will continue to invest in that also and our ability to stay ahead is, I think, very strong. So I think from a forecast perspective, I expect global EP growth to accelerate. it is in the teens right now. It will accelerate in the second half. For sure and outperforming the market. And I expect that momentum that we are building this year to carry through to next year. And I think we will get an additional boost, into this EP portfolio. With our new LAA device I think feedback there has been extremely positive. And we filed with the FDA. I think here, I will probably feel a little bit more comfortable saying, yeah. I can see if I can see a potential to be able to get this approved by year end. And then with that, we will have strong momentum going into next year with both rollout of Tactiflex Duo in The US continued acceleration of Bolt in the US, launching our next generation LAA device also. So I see that momentum continue into next year. Matt Taylor: Great. Thanks so much. Yep. Operator: Thank you. Our next question comes from Travis Steed from BofA Securities. Your line is open. Travis Steed: Hey, Robert. Thanks for taking the question. I guess as w”